Sorrento Therpt (SRNE)
$9.85
0.35 (3.68%)
4:18 EST
SRNE Stock Quote Delayed 30 Minutes
Previous Close
-
Market Cap
1.14B
PE Ratio
49.25
EPS
0.2
Volume (Avg. Vol.)
19,486
Day's Range
9.50 - 9.50
52-Week Range
1.55 - 19.39
Dividend & Yield
N/A (N/A)
SRNE Stock Predictions, Articles, and Sorrento Therpt News
- From InvestorPlace
- From the Web
Sorrento Stock Is Little More Than a Day Trade Now
Nearly a third of SRNE stock's float has been sold short. This sets up a catalyst for a short-term move, but avoid a long-term investment.
Government and Institutional Support Are Positives for Sorrento Stock
Sorrento just received a grant of up to $34 million from Washington, while multiple institutions own meaningful amounts of SRNE stock.
SRNE Stock: California Testing Approval Stokes Sorrento Therapeutics
Sorrento Therapeutics is poised to roll out clinical testing trials in California. SRNE stock is up in pre-market trading on Wednesday as the country continues to post record Covid-19 diagnoses and hospitalizations.
Sorrento Therapeutics Remains a Buy Between $6 and $6.50
Sorrento Therapeutics has seen SRNE stock close between $5.76 and $8.20 in the past month. Here’s why it’s time for investors to be careful.
Covid-19 Vaccine Makers Still Make Sense, Including Sorrento Therapeutics
SRNE stock fell out of favor as bigger vaccine developers grabbed the headlines but that may change soon.
Don’t Chase the Rebound in Sorrento — It’s Not Worth the Risk
By
Thomas Niel
SRNE stock may be bouncing back, but given its grab bag of issues, skip out on this fading coronavirus play.
The Shock and Awe of Sorrento Therapeutics Is Long Gone
Sorrento Therapeutics was an early pandemic winner. But as the world closes in on multiple vaccines, SRNE stock looks to be too late.
Hopefuls Back Sorrento Therapeutics But Time Is a Factor
Investors seeking a longshot coronavirus play continue to eye SRNE stock despite Sorrento Therapeutics' high risk and continued volatility.
Sorrento Stock Doesn’t Offer Any Upside as Vaccine Frontrunners Emerge
The Covid-19 race is close to ending. It seems unlikely that Sorrento stock can pull a rabbit out of a hat with the frontrunners emerging.
Windows of Opportunity Are Tightening for Sorrento Therapeutics
Thanks to Sorrento Therapeutics’ all-out pivot to address the Covid-19 pandemic, SRNE stock initially became one of the most popular investments. But as both the vaccine and treatment race tighten, the risks multiply.
Don’t Bail on Sorrento Therapeutics Stock Just Yet
SRNE stock has tumbled as larger players have shown progress toward a vaccine. But this isn't just a vaccine play, and the story is far from over.
Avoid Sorrento Therapeutics, Which Is Still Burning Cash With No End In Sight
Avoid Sorrento Therapeutics which is still burning cash with no end in sight. SRNE stock will become more diluted as the company consistently raises cash.
Pfizer, Moderna Lead the Vaccine Race: Here’s Where 7 Other Top Vaccine Stocks Stand
As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here’s how this affects other Covid-19-related biotech stocks.
Sorrento Therapeutics Hoping Better Late Than Never Works in Vaccine Competition
In this competition, Sorrento is a different beast because it's not just working on a vaccine, it's working on Covid-19 testing, neutralizing antibodies and preventive “shields,” among other products. That's a relevant, robust pipeline, but it hasn't been enough to prevent SRNE stock from sliding 61% from its 52-week high.
The Breakthrough for Sorrento Could Be Just Around the Corner
If you'd like to wager on a company with a packed clinical pipeline featuring potential Covid-19 treatments, SRNE stock is a great choice.
A Vulnerable Pipeline Continues to Weigh Down Sorrento Stock
Sorrento stock continues to be weighed down by the company's inefficacious product pipeline making it an incredibly risky investment.
Unless Sorrento Makes Solid Progress Soon, It Will Likely Go Below $5
SRNE stock is a speculative play in the race to develop a Covid-19 therapy
Is It Time to Buy Sorrento Stock After Its Month-Long Swoon?
Sorrento stock has lost 50% over the past month. Investors have grown impatient with the company's Covid-19 efforts. Time to buy or sell?
I Would Not Be Surprised If SRNE Stock Trades Below $5
SRNE stock is a purely speculative bet. The company has a deep pipeline of Covid-19 programs. But there is little progress or positive outcome.
Sorrento Stock Is Too Sick to Resuscitate
By
Joel Baglole
Sorrento Therapeutics stock has been punished in recent weeks. In this article we look at why Sorrento stock has fallen 50% since mid-October, and if the company's fortunes can be revived.

Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
Buy